Simile hits $2B valuation 5 months after Series A
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Simile raised a $200M Series B at a $2B valuation, just five months after emerging from stealth with a $100M Series A led by Index Ventures.
- Greenoaks led the Series B round with participation from Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition, and CVS Health Ventures.
- CVS Health Ventures is both a participating investor in the round and one of Simile's marquee customers, signaling enterprise healthcare demand for synthetic consumer research.
- Simile sells simulated users for marketing and product research and was founded by Stanford PhD Joon Sung Park, whose dissertation project "Smallville" featured AI agents living simulated human lives including hosting parties.
- Simile's stated mission of simulating "all eight billion people on earth, accurately and honestly" is dismissed as preposterous in the source, since humans are unpredictable and guided by both emotions and reason.
- Aaru, a competing synthetic-user startup, raised its own Series A in December at a $1B valuation, showing the category is drawing multiple nine-figure bets.
Why it matters: Simile's jump to a $2B valuation just five months after a $100M Series A shows how aggressively VCs are pricing synthetic-user startups, while CVS Health both writing a check and buying the product signals that enterprise healthcare brands are willing to anchor the customer base for AI-generated consumer research.
Ask SkimNews
